Amgen psoriasis candidate bests J&J's Stelara; FDA slams Sciecure insomnia drug sales materials;

> Amgen's ($AMGN) psoriasis drug brodalumab beat Johnson & Johnson's ($JNJ) Stelara at clearing patients' skin in a late-stage study, in the latest round of data for a soon-to-be-upended psoriasis market. Report

> The FDA's pharma marketing police slammed Sciecure Pharma for a lack of fair balance in a sales aid for its insomnia drug Doral. Report

> South Carolina-based Afaxys Pharmaceuticals says its emergency contraceptive, ella, is now available nationwide in the U.S.; the company is particularly focusing on public health providers, urgent centers, ERs and student health centers. Release

> The U.K. drugmaker BTG said it has finally launched its varicose vein treatment Varithena in the U.S., 18 years after it bought the technology. Release

And Finally... Servier is gambling up to $1B on Intarcia's late-stage drug-emitting diabetes device. Report

Suggested Articles

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.